Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Sales Slip, Merck & Co. Plans 7,200 Job Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

Facing lower sales of Vytorin, Singulair and Gardasil, on top of recent pipeline disappointments, Merck implements a new restructuring initiative.

Related Content

Sanofi Pasteur To File Quick Response To cGMP Violations At French Plant
Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Merck Delays Migraine Drug Filing; Q1 Sales Fall Short of Analyst Expectations
HCV Among Merck’s Gains With Schering, But Future Moves Still Murky
Merck’s Clark: 2009 is a Year of Fundamental Change
Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet
Merck Commercial Model: Expand Customer Base, Tighten Marketing Spend
FDA Seeks Outcomes Data For Merck’s MK-0524A
FDA Seeks Outcomes Data For Merck’s MK-0524A
Schering-Plough Cutback Target: $1.5 Billion





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts